Loading...

Evaluation Form

  • Home
  • Evaluation Form

Acute Hepatic Porphyrias: Recognition, Differential Diagnosis, and Treatment Strategies

CME Satellite Symposium at the CNS - March 21, 2026

Dana Point, CA

I am a *
Please rate how well the following learning objectives were met:
Recognize the hallmark signs and symptoms of acute hepatic porphyrias
Differentiate AHP from other acute neurologic, gastrointestinal, and metabolic disorders with overlapping presentations
Identify appropriate diagnostic tests and timing to confirm AHP in symptomatic patients
Apply evidence-based, guideline-supported treatment strategies for managing AHP during acute attacks
Integrate consensus recommendations into clinical decision-making for both immediate and follow-up care
Was the presentation fair-balanced and objective? *
The speaker was knowledgeable, effective, and had expertise regarding porphyrias *
The presentation improved my knowledge and competence in managing patients with porphyrias *
Were you satisfied with the presentation? *
In a patient with suspicion for Acute Intermittent Porphyria (AIP), the most informative diagnostic in between the attacks test is: *
Which is the most appropriate INITIAL STEP in managing a suspected acute attack of Acute Hepatic Porphyria (AHP)? *
What are the autonomic signs commonly encountered in AHPs? *
Which medication is most likely to precipitate an acute porphyria attack and should be avoided in suspected AHP cases? *
Electrolyte abnormalities and neuropathy are common often overlooked features of acute attacks *
Which of the following is NOT a symptom of AHP? *
Which neurologic feature is most characteristic during an acute attack of AHP? *
34 yr woman with Dx of AIP shows severe abdominal pain, nausea, new-onet proximal muscle weakness. Reports new insomnia. Has TACH, hyponatremia, urinary levels of porphobilinogen are elevated. What is next step? *
How often do you CURRENTLY use this strategy? I make sure to check a spot urine porphobilinogen (PBG) *
Now that you have heard this presentation, how often do you PLAN TO USE the above strategy? *
How often do you CURRENTLY use this strategy? I treat neuro crises in HT1 with intravenous dextrose and nitisinone, and use hemin in severe cases *
Now that you have heard this presentation, how often do you PLAN TO USE the above strategy? *
How often do you CURRENTLY use this strategy? I consult online resources to identify medication triggers of AHP? *
Now that you have heard this presentation, how often do you PLAN TO USE the above strategy? *
Indicate at least one more change you will implement as a result of attending this presentation
List any comments or questions you still have
Once you submit this evaluation, you will receive an email with a link to your certificate.